What’s in Your Basket? Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Durvalumab/Tremelimumab for HCC in Patients Undergoing Liver Transplant
April 24th 2023Promising efficacy has been seen with the use of immunotherapy for the management of patients with hepatocellular carcinoma, Now, durvalumab and tremelimumab combination therapy is being studied for this patient population listed for a liver transplant.
Read More
NRG/RTOG 1112 Study Evaluates SBRT Plus Sorafenib for Hepatocellular Carcinoma
March 22nd 2023Laura A. Dawson, MD, FRCPC, discusses the NRG/RTOG 1112 study for patients with hepatocellular carcinoma which evaluated stereotactic body radiation therapy followed by sorafenib compared with sorafenib alone.
Watch
Determining Need for Biopsy in Suspected Hepatocellular Carcinoma
February 27th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Daneng Li, MD, discussed what role a biopsy and other procedures might serve in a patient with a LI-RADS 5 liver lesion. This is the first of 2 articles based on this event.
Read More
Physicians Discuss Their Impressions of Recent IO/TKI Trials for HCC
February 6th 2023During a Targeted Oncology case-based roundtable event, Amit Singal, MD, and participants discussed the significance of LEAP-002 and other trials investigating immunotherapy plus tyrosine kinase inhibitor therapy in patients with hepatocellular carcinoma.
Read More
SBRT Plus Sorafenib Improves Survival in Locally Advanced HCC
February 1st 2023In an interview with Targeted Oncology, Laura Dawson, MD, FRCPC, discussed the results of the phase 3 NRG/RTOG 1112 study of SBRT followed by sorafenib compared with sorafenib alone in locally advanced hepatocellular carcinoma.
Read More
Sorafenib in Combination with SBRT Extends Survival in Locally Advanced HCC
January 21st 2023The phase 3 NRG/RTOG 1112 adds to the body of evidence for the role of external beam radiation, bringing SBRT to the armamentarium of treatment for patients with locally advanced hepatocelluar carcinoma, according to Laura Dawson, MD, FRCPC.
Read More
Early Trial Results Show Promise for Combination of Lenvatinib, TACE, and Microwave Ablation in HCC
January 20th 2023Results from the phase 2 Talem trial, presented at the 2023 Gastrointestinal Cancers Symposium, showed the promising signs of efficacy, anti-tumor activity, and tolerable adverse events when combining blank-microsphere transarterial chemoembolization with lenvatinib and sequential microwave ablation for patients with HCC.
Read More
Addition of Pembrolizumab to Lenvatinib for HCC Elicits Similar Scores in LEAP-002
January 20th 2023Data from the health-related quality of life analysis of the LEAP-002 study showed similar scores with the addition of pembrolizumab to lenvatinib vs placebo plus lenvatinib in patients with hepatocellular carcinoma.
Read More
Lenvatinib Elicits Survival Benefit After Progression on Immunotherapy in HCC
January 20th 2023Patients with advanced hepatocellular carcinoma who were treated with lenvatinib following progression on immunotherapy had a median overall survival of 12.8 months and progression-free survival of 3.7 months.
Read More
Adjuvant Atezolizumab Plus Bevacizumab Improve RFS in Early-Stage Hepatocellular Carcinoma
January 19th 2023In IMbrave050, the risk of disease recurrence or death was decreased with adjuvant atezolizumab and bevacizumab compared with active surveillance in patients with early-stage hepatocellular carcinoma.
Read More